Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

1. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93 387 391

2. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2005 Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 1180 1184

3. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41 1690 1696

4. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2005 Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 9067 9072

5. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2005 REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2 416 422

6. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100 229 235

7. McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM 2006 Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol 28 99 105

8. MoherDSchulzKFAltmanD 2001 The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285 1987 1991

9. VandenbrouckeJPvon ElmEAltmanDGGotzschePCMulrowCDPocockSJPooleCSchlesselmanJJEggerM 2007 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4 e297 doi:10.1371/journal.pmed.0040297

10. LiberatiAAltmanDGTetzlaffJMulrowCGotzschePCIoannidisJPClarkeMDevereauxPJKleijnenJMoherD 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6 e1000100 doi:10.1371/journal.pmed.1000100

11. MoherDHopewellSSchulzKFMontoriVGotzschePCDevereauxPJElbourneDEggerMAltmanDG 2010 CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340 c869

12. SimonRAltmanDG 1994 Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 979 985

13. AltmanDGLymanGH 1998 Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52 289 303

14. HallPAGoingJJ 1999 Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 35 489 494

15. RileyRDAbramsKRSuttonAJLambertPCJonesDRHeneyDBurchillSA 2003 Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88 1191 1198

16. SauerbreiW 2005 Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv Otorhinolaryngol 62 184 200

17. KyzasPALoizouKTIoannidisJP 2005 Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97 1043 1055

18. KyzasPADenaxa-KyzaDIoannidisJP 2007 Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99 236 243

19. RileyRDSauerbreiWAltmanDG 2009 Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100 1219 1229

20. MallettSTimmerASauerbreiWAltmanDG 2010 Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 102 173 180

21. SigounasDETatsioniAChristodoulouDKTsianosEVIoannidisJP 2011 New Prognostic Markers for Outcome of Acute Pancreatitis: Overview of Reporting in 184 Studies. Pancreas 40 522 532

22. EggerMJuniPBartlettC 2001 Value of flow diagrams in reports of randomized controlled trials. JAMA 285 1996 1999

23. SchulzKFAltmanDGMoherD 2010 CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340 c332

24. KokMHolm-WigerupCHauptmannMMichalidesRStalOLinnSLandbergG 2009 Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 101 1725 1729

25. GalonJCostesASanchez-CaboFKirilovskyAMlecnikBLagorce-PagesCTosoliniMCamusMBergerAWindPZinzindohoueFBrunevalPCugnencPHTrajanoskiZFridmanWHPagesF 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 1960 1964

26. KawakamiKBrabenderJLordRVGroshenSGreenwaldBDKrasnaMJYinJFleisherASAbrahamJMBeerDGSidranskyDHussHTDemeesterTREadsCLairdPWIlsonDHKelsenDPHarpoleDMooreMBDanenbergKDDanenbergPVMeltzerSJ 2000 Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92 1805 1811

27. NunesRALiXKangSPBursteinHRobertsLCarneyWBlackwellKRyanPBorgesVIglehartJDFriedmanPHarrisLN 2009 Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers 24 1 10

28. PopatSMatakidouAHoulstonRS 2004 Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 529 536

29. FoekensJALookMPBolt-de VriesJMeijer-van GelderMEvan PuttenWLKlijnJG 1999 Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79 300 307

30. PaschkaPMarcucciGRuppertASWhitmanSPMrozekKMaharryKLangerCBaldusCDZhaoWPowellBLBaerMRCarrollAJCaligiuriMAKolitzJELarsonRABloomfieldCD 2008 Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26 4595 4602

31. ChoiJYBarlowWEAlbainKSHongCCBlancoJGLivingstonRBDavisWRaeJMYehITHutchinsLFRavdinPMMartinoSLyssAPOsborneCKAbeloffMDHayesDFAmbrosoneCB 2009 Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 15 5258 5266

32. HutchinsLFGreenSJRavdinPMLewDMartinoSAbeloffMLyssAPAllredCRivkinSEOsborneCK 2005 Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23 8313 8321

33. BurtonAAltmanDG 2004 Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91 4 8

34. de MascarelIBonichonFDurandMMauriacLMacGroganGSoubeyranIPicotVAvrilACoindreJMTrojaniM 1998 Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 34 58 65

35. ChoHKangESKimYTKimJH 2009 Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 27 313 323

36. HartmannEFernandezVMorenoVVallsJHernandezLBoschFAbrisquetaPKlapperWDreylingMHosterEMuller-HermelinkHKOttGRosenwaldACampoE 2008 Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 26 4966 4972

37. DjidjaMCClaudeESnelMFScrivenPFranceseSCarolanVClenchMR 2009 MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. J Proteome Res 8 4876 4884

38. National Cancer Institute 2007 Best practices for biospecimen resources. http://biospecimens.cancer.gov/global/pdfs/NCI_Best_Practices_060507.pdf

39. Leyland-JonesBRAmbrosoneCBBartlettJEllisMJEnosRARajiAPinsMRZujewskiJAHewittSMForbesJFAbramovitzMBragaSCardosoFHarbeckNDenkertCJewellSD 2008 Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 26 5638 5644

40. International Society for Biological and Environmental Repositories (ISBER) 2008 2008 Best practices for repositories: Collection, storage, retrieval and distribution of biological materials for research. Cell Preserv Technol 6 5 58

41. MooreHMKellyABJewellSDMcShaneLMClarkDPGreenspanRHainautPHayesDFKimPMansfieldEPotapovaORiegmanPRubinsteinYSeijoESomiariSWatsonPWeierHUZhuCVaughtJ 2011 Biospecimen Reporting for Improved Study Quality (BRISQ). Biopreservation Biobanking 9 57 70

42. BilousMDowsettMHannaWIsolaJLebeauAMorenoAPenault-LlorcaFRuschoffJTomasicGvan dV 2003 Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16 173 182

43. HammondMEBarkerPTaubeSGutmanS 2003 Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol 11 103 106

44. van den BroekLJCMvan de VijverMJ 2000 Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol 8 316 321

45. FergenbaumJHGarcia-ClosasMHewittSMLissowskaJSakodaLCShermanME 2004 Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13 667 672

46. RansohoffDF 2005 Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 142 149

47. BertagnolliMMWarrenRSNiedzwieckiDMuellerEComptonCCRedstonMHallMHahnHPJewellSDMayerRJGoldbergRMSaltzLBLodaM 2009 p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 15 2116 2122

48. de GraeffPCrijnsAPTen HoorKAKlipHGHollemaHOienKBartlettJMWismanGBde BockGHde VriesEGdeJSvan der ZeeAG 2008 The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99 341 349

49. PressMFHungGGodolphinWSlamonDJ 1994 Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 2771 2777

50. RomeroHSchneiderJ 1995 Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits. Eur J Cancer 31A 1020 1021

51. McShaneLMAamodtRCordon-CardoCCoteRFaraggiDFradetYGrossmanHBPengATaubeSEWaldmanFM 2000 Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 6 1854 1864

52. NietoYWoodsJNawazFBaronAJonesRBShpallEJNawazS 2007 Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 97 391 397

53. GazicBPizemJBrackoMCuferTBorstnarSPohar-MarinsekZUs-KrasovecM 2008 S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology 19 294 302

54. JensenVPrasadARSmithARajuMWendelCSSchmelzMLeyvaWWarnekeJKrouseRS 2010 Prognostic criteria for squamous cell cancer of the skin. J Surg Res 159 509 516

55. VandenbrouckeJP 1991 Prospective or retrospective: what's in a name? BMJ 302 249 250

56. KivelaTGrambschPM 2003 Evaluation of sampling strategies for modeling survival of uveal malignant melanoma. Invest Ophthalmol Vis Sci 44 3288 3293

57. BreslowNEChatterjeeN 1999 Design and analysis of two-phase studies with binary outcome applied to Wilms tumour prognosis. Appl Stat 48 457 468

58. GrayRJ 2009 Weighted analyses for cohort sampling designs. Lifetime Data Analysis 15 24 40

59. FoekensJARiesCLookMPGippner-SteppertCKlijnJGJochumM 2003 The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res 63 337 341

60. OsmanIYeeHTanejaSSLevinsonBZeleniuch-JacquotteAChangCNobertCNanusDM 2004 Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 10 4096 4100

61. SchemperMSmithTL 1996 A note on quantifying follow-up in studies of failure time. Control Clin Trials 17 343 346

62. ClarkTGAltmanDGDe StavolaBL 2002 Quantification of the completeness of follow-up. Lancet 359 1309 1310

63. WuYTakkenbergJJGrunkemeierGL 2008 Measuring follow-up completeness. Ann Thorac Surg 85 1155 1157

64. AltmanDGDe StavolaBLLoveSBStepniewskaKA 1995 Review of survival analyses published in cancer journals. Br J Cancer 72 511 518

65. CerianiRLChanCMBarattaFSOzzelloLDeRosaCMHabifDV 1992 Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer 51 343 354

66. SauerbreiWRoystonPBojarHSchmoorCSchumacherM 1999 Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 79 1752 1760

67. HudisCABarlowWECostantinoJPGrayRJPritchardKIChapmanJASparanoJAHunsbergerSEnosRAGelberRDZujewskiJA 2007 Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25 2127 2132

68. GoodwinPJEnnisMPritchardKIKooJHoodN 2009 Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27 3757 3763

69. van WalravenCDavisDForsterAJWellsGA 2004 Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 57 672 682

70. BeyersmannJWolkewitzMSchumacherM 2008 The impact of time-dependent bias in proportional hazards modelling. Stat Med 27 6439 6454

71. RochonJ 1999 Issues in adjusting for covariates arising postrandomization in clinical trials. Drug Inf J 33 1219 1228

72. FisherLDLinDY 1999 Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20 145 157

73. AndersenPSkovgaardLT 2010 Regression with linear predictors New York Springer

74. CorteseGAndersenPK 2010 Competing risks and time-dependent covariates. Biom J 52 138 158

75. BarrattPLSeymourMTStenningSPGeorgiadesIWalkerCBirbeckKQuirkeP 2002 DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360 1381 1391

76. PopatSChenZZhaoDPanHHearleNChandlerIShaoYAherneWHoulstonR 2006 A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 17 1810 1817

77. BraunMSRichmanSDThompsonLDalyCLMeadeAMAdlardJWAllanJMParmarMKQuirkePSeymourMT 2009 Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27 5519 5528

78. SchmoorCSauerbreiWSchumacherM 2000 Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 19 441 452

79. McShaneLMSimonR 2001 Statistical methods for the analysis of prognostic factor studies. GospodarowiczMKHensonDEHutterRVPO'SullivanBSobinLH Prognostic factors in cancer New York Wiley-Liss 37 48

80. HsiehFYLavoriPW 2000 Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 21 552 560

81. GillSSargentD 2006 End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 11 624 629

82. HarrellFEJrLeeKLMatcharDBReichertTA 1985 Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69 1071 1077

83. SchumacherMHollanderNSchwarzerGSauerbreiW 2006 Prognostic factor studies. CrowleyJ Handbook of Statistics in Clinical Oncology New York Marcel Dekker

84. PeduzziPConcatoJFeinsteinARHolfordTR 1995 Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48 1503 1510

85. FeinsteinAR 1996 Multivariable Analysis: an Introduction New Haven Yale University Press

86. VittinghoffEMcCullochCE 2007 Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165 710 718

87. LubinJHGailMH 1990 On power and sample size for studying features of the relative odds of disease. Am J Epidemiol 131 552 566

88. BrundageMDDaviesDMackillopWJ 2002 Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 1037 1057

89. BentzenSM 2001 Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 49 513 518

90. RileyRDHeneyDJonesDRSuttonAJLambertPCAbramsKRYoungBWailooAJBurchillSA 2004 A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10 4 12

91. International Committee of Medical Journal Editors. 2010 Uniform Requirements for Manuscripts Submitted to Biomedical Journals. http://icmje.org/urm_full.pdf

92. ConcatoJFeinsteinARHolfordTR 1993 The risk of determining risk with multivariable models. Ann Intern Med 118 201 210

93. BagleySCWhiteHGolombBA 2001 Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol 54 979 985

94. PocockSJCollierTJDandreoKJDe StavolaBLGoldmanMBKalishLAKastenLEMcCormackVA 2004 Issues in the reporting of epidemiological studies: a survey of recent practice. BMJ 329 883

95. OttenbacherKJOttenbacherHRToothLOstirGV 2004 A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol 57 1147 1152

96. KlebanoffMAColeSR 2008 Use of multiple imputation in the epidemiologic literature. Am J Epidemiol 168 355 357

97. KhoMEEvaKWCookDJBrouwersMC 2008 The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts. J Clin Epidemiol 61 1241 1249

98. FalagasMEGrigoriTIoannidouE 2009 A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. J Clin Epidemiol 62 227 231

99. HarrellFEJrLeeKLMarkDB 1996 Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 361 387

100. HosmerDWLemeshowS 2000 Applied Logistic Regression New York John Wiley and Sons Ltd

101. HarrellFEJr 2001 Regression modeling strategies with applications to linear models, logistic regression, and survival analysis New York Springer

102. BradburnMJClarkTGLoveSBAltmanDG 2003 Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer 89 605 611

103. BradburnMJClarkTGLoveSBAltmanDG 2003 Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br J Cancer 89 431 436

104. ClarkTGBradburnMJLoveSBAltmanDG 2003 Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 89 781 786

105. ClarkTGBradburnMJLoveSBAltmanDG 2003 Survival analysis part I: basic concepts and first analyses. Br J Cancer 89 232 238

106. VittinghoffEGliddenDVMcCullochCEShiboskiSC 2005 Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models New York, NY Springer Science+Business Media Inc

107. SchumacherMHolländerNSchwarzerGSauerbreiW 2006 Prognostic factor studies. CrowleyJAnkerstDP Handbook of Statistics in Clinical Oncology Boca Raton, Florida Chapman & Hall/CRC Press 289 333

108. SauerbreiWRoystonPBinderH 2007 Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26 5512 5528

109. HosmerDWLemeshowSMayS 2008 Applied survival analysis: Regression modeling of time-to-event data Hoboken, NJ Wiley-Interscience

110. RoystonPSauerbreiW 2008 Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables Chichester John Wiley

111. DupontWD 2009 Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data Cambridge University Press

112. JonesRLSalterJA'HernRNerurkarAPartonMReis-FilhoJSSmithIEDowsettM 2009 The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116 53 68

113. AltmanDG 1991 Preparing to analyse data. Practical statistics for medical research London Chapman and Hall 122 151

114. BlettnerMSauerbreiW 1993 Influence of model-building strategies on the results of a case-control study. Stat Med 12 1325 1338

115. MallowsC 1998 The zeroth problem. Am Stat 52 1 9

116. ChatfieldC 2002 Confessions of a pragmatic statistician. Statistician 51 1 20

117. BailarJCI 2006 How to distort the scientific record without actually lying: truth, and the arts of science. Eur J Oncol 11 217 224

118. LamkinDMSpitzDRShahzadMMZimmermanBLenihanDJDegeestKLubaroffDMShinnEHSoodAKLutgendorfSK 2009 Glucose as a prognostic factor in ovarian carcinoma. Cancer 115 1021 1027

119. LughezzaniGJeldresCIsbarnHSunMShariatSFAlaskerAPharandDWidmerHArjanePGraefenMMontorsiFPerrottePKarakiewiczPI 2009 Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 45 3291 3297

120. WolkewitzMVonbergRPGrundmannHBeyersmannJGastmeierPBarwolffSGeffersCBehnkeMRudenHSchumacherM 2008 Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crit Care 12 R44

121. MarubiniEValsecchiM 1995 Analysing Survival Data from Clinical Trials and Observational Studies New York John Wiley and Sons Ltd

122. TherneauTGrambschP 2001 Modeling Survival Data: Extending the Cox Model New York Springer-Verlag New York Inc

123. RoystonPParmarMK 2002 Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21 2175 2197

124. SimonRKornELMcShaneLMRadmacherMDWrightGZhaoY 2004 Design and analysis of DNA microarray investigations New York Springer

125. SteyerbergEW 2009 Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating New York Springer-Verlag

126. HastieTTibshiraniRFriedmanJH 2009 The Elements of Statistical Learning: Data Mining, Inference, and Prediction Springer-Verlag New York Inc

127. WintersZELeekRDBradburnMJNorburyCJHarrisAL 2003 Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 5 R242 R249

128. van BuurenSBoshuizenHCKnookDL 1999 Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18 681 694

129. KenwardMGCarpenterJ 2007 Multiple imputation: current perspectives. Stat Methods Med Res 16 199 218

130. SterneJACWhiteIRCarlinJBSprattMRoystonPKenwardMGWoodAMCarpenterJR 2009 Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338 b2393

131. WhiteIRRoystonP 2009 Imputing missing covariate values for the Cox model. Stat Med 28 1982 1998

132. EfficaceFBottomleyASmitEFLianesPLegrandCDebruyneCSchramelFSmitHJGaafarRBiesmaBManegoldCCoensCGiacconeGVanMJ 2006 Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17 1698 1704

133. SauerbreiW 1999 The use of resampling methods to simplify regression models in medical statistics. Appl Stat 48 313 329

134. PaceNL 2008 Independent predictors from stepwise logistic regression may be nothing more than publishable P values. Anesth Analg 107 1775 1778

135. CoradiniDDaidoneMGBoracchiPBiganzoliEOrianaSBrescianiGPellizzaroCTomasicGDiFGMarubiniE 2000 Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 18 2702 2709

136. LutterbachJSauerbreiWGuttenbergerR 2003 Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 179 8 15

137. GrayRJ 1992 Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87 942 951

138. AbrahamowiczMMacKenzieTA 2007 Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Stat Med 26 392 408

139. SauerbreiWRoystonPLookM 2007 A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biom J 49 453 473

140. BelsleyDAKuhEWelschRE 1980 Regression diagnostics: Identifying influential data and sources of collinearity New York Wiley

141. BabyakMA 2004 What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 66 411 421

142. StockerGOttKHenningsenNBeckerKHapfelmeierALordickFHoisSPlaschkeSHoflerHKellerG 2009 CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer 45 3326 3335

143. RajputABTurbinDACheangMCVoducDKLeungSGelmonKAGilksCBHuntsmanDG 2008 Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat 107 249 257

144. AltmanDGRoystonP 2000 What do we mean by validating a prognostic model? Stat Med 19 453 473

145. AltmanDGVergouweYRoystonPMoonsKG 2009 Prognosis and prognostic research: validating a prognostic model. BMJ 338 b605

146. SimonRMPaikSHayesDF 2009 Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101 1446 1452

147. DavisonACHinkleyDV 1997 Bootstrap Methods and Their Application Cambridge University Press

148. CarpenterJBithellJ 2000 Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19 1141 1164

149. ChernickMR 2008 Bootstrap Methods: A Guide for Practitioners and Researchers New York Wiley

150. PierceBLBallard-BarbashRBernsteinLBaumgartnerRNNeuhouserMLWenerMHBaumgartnerKBGillilandFDSorensenBEMcTiernanAUlrichCM 2009 Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27 3437 3444

151. LiaoWCLinJTWuCYHuangSPLinMTWuASHuangYJWuMS 2008 Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14 428 434

152. PentheroudakisGKalogerasKTWirtzRMGrimaniIZografosGGogasHStroppUPectasidesDSkarlosDHennigGSamantasEBafaloukosDPapakostasPKalofonosHPPavlidisNFountzilasG 2009 Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116 131 143

153. RoystonPAltmanDGSauerbreiW 2006 Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25 127 141

154. MalatsNBustosANascimentoCMFernandezFRivasMPuenteDKogevinasMRealFX 2005 P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 678 686

155. ClarkGMZborowskiDMCulbertsonJLWhiteheadMSavoieMSeymourLShepherdFA 2006 Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 1 837 846

156. von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJP 2007 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4 e296 doi:10.1371/journal.pmed.0040296

157. PfistererJKommossFSauerbreiWRenzHduBAKiechle-SchwarzMPfleidererA 1994 Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 74 2509 2515

158. WadehraMNatarajanSSeligsonDBWilliamsCJHummerAJHedvatCBraunJSoslowRA 2006 Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 107 90 98

159. KommossFPfistererJIdrisTGieseESauerbreiWSchaferWThomeMPfleidererA 1994 Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol 16 203 210

160. AltmanDG 1991 Practical statistics for medical research London Chapman and Hall

161. BlandJMAltmanDG 1998 Survival probabilities (the Kaplan-Meier method). BMJ 317 1572

162. PocockSJClaytonTCAltmanDG 2002 Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359 1686 1689

163. TzoulakiILiberopoulosGIoannidisJP 2009 Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302 2345 2352

164. KattanMW 2004 Evaluating a new marker's predictive contribution. Clin Cancer Res 10 822 824

165. PepeMSJanesHLongtonGLeisenringWNewcombP 2004 Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 882 890

166. WatermannDMadjarHSauerbreiWHirtVPrompelerHStickelerE 2004 Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep 11 905 910

167. VormittagLGleissAScheithauerWLangFLaengleFKornekGV 2009 Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology 77 140 146

168. EfronBTibshiraniRJ 1994 Introduction to the bootstrap Taylor & Francis Ltd

169. BradburyPAZhaiRMaCXuWHopkinsJKulkeMJAsomaningKWangZSuLHeistRSLynchTJWainJCChristianiDLiuG 2009 Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 15 4680 4685

170. HafftyBGYangQMoranMSTanARReissM 2008 Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71 1006 1013

171. BlackfordASerranoOKWolfgangCLParmigianiGJonesSZhangXParsonsDWLinJCLearyRJEshlemanJRGogginsMJaffeeEMIacobuzio-DonahueCAMaitraACameronJLOlinoKSchulickRWinterJHermanJMLaheruDKleinAPVogelsteinBKinzlerKWVelculescuVEHrubanRH 2009 SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 15 4674 4679

172. AltmanDGSchulzKFMoherDEggerMDavidoffFElbourneDGøtzschePCLangT 2001 The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134 663 694

173. Gould RothbergBEBrackenMBRimmDL 2009 Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101 452 474

174. WhiteleyWChongWLSenguptaASandercockP 2009 Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40 e380 e389

175. MupparapuMKimIH 2007 Calcified carotid artery atheroma and stroke: a systematic review. J Am Dent Assoc 138 483 492

176. HemingwayHPhilipsonPChenRFitzpatrickNKDamantJShipleyMAbramsKRMorenoSMcAllisterKSPalmerSKaskiJCTimmisADHingoraniAD 2010 Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 7 e1000286 doi:10.1371/journal.pmed.1000286

177. HuberGFZulligLSoltermannARoessleMGrafNHaerleSKStuderGJochumWMochHStoeckliSJ 2011 Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 11 217 218

178. HamiltonHKRoseAEChristosPJShapiroRLBermanRSMazumdarMMaMWKrichDLiebesLBrooksPCOsmanI 2010 Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med 8 19

179. YanYSklirisGPPennerCChooniedass-KothariSCooperCNugentZBlanchardAWatsonPHMyalYMurphyLCLeygueE 2009 Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res 11 R67

180. IgnatiadisMXenidisNPerrakiMApostolakiSPolitakiEKafousiMStathopoulosENStathopoulouALianidouEChlouverakisGSotiriouCGeorgouliasVMavroudisD 2007 Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25 5194 5202

181. GregorcVSpreaficoAFlorianiIColomboBLudoviniVPistolaLBellezzaGViganoMGVillaECortiA 2007 Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer 110 845 853

182. StefanssonIMSalvesenHBAkslenLA 2004 Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22 1242 1252

183. LoussouarnDCampionLLeclairFCamponeMCharbonnelCRicolleauGGouraudWBatailleRJezequelP 2009 Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer 101 166 173

184. du BoisAReussAPujade-LauraineEHarterPRay-CoquardIPfistererJ 2009 Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115 1234 1244

185. FreidlinBMcShaneLMKornEL 2010 Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102 152 160

186. AssmannSFPocockSJEnosLEKastenLE 2000 Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 1064 1069

187. LagakosSW 2006 The challenge of subgroup analyses–reporting without distorting. N Engl J Med 354 1667 1669

188. AltmanDGBlandJM 2003 Interaction revisited: the difference between two estimates. BMJ 326 219

189. GreenlandS 1983 Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med 2 243 251

190. WillettWC 2008 The search for truth must go beyond statistics. Epidemiology 19 655 656

191. RoystonPSauerbreiW 2004 A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 23 2509 2525

192. RoystonPSauerbreiWRitchieA 2004 Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90 794 799

193. BonettiMGelberRD 2000 A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19 2595 2609

194. RoystonPSauerbreiW 2008 Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol 26 1397 1399

195. DondersARvan der HeijdenGJStijnenTMoonsKG 2006 Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59 1087 1091

196. van der HeijdenGJDondersARStijnenTMoonsKG 2006 Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 59 1102 1109

197. Mathoulin-PelissierSGourgou-BourgadeSBonnetainFKramarA 2008 Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 26 3721 3726

198. AltmanDGLausenBSauerbreiWSchumacherM 1994 Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86 829 835

199. HolländerNSauerbreiWSchumacherM 2004 Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint. Stat Med 23 1701 1713

200. van WalravenCHartRG 2008 Leave ‘em alone - why continuous variables should be analyzed as such. Neuroepidemiology 30 138 139

201. VickersAJLiljaH 2009 Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem 55 15 17

202. TaylorJMAnkerstDPAndridgeRR 2008 Validation of biomarker-based risk prediction models. Clin Cancer Res 14 5977 5983

203. RoystonPAltmanDG 1994 Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Applied Statistics 43 467

204. IoannidisJP 2008 Why most discovered true associations are inflated. Epidemiology 19 640 648

205. DwanKAltmanDGArnaizJABloomJChanAWCroninEDecullierEEasterbrookPJVonEEGambleCGhersiDIoannidisJPSimesJWilliamsonPR 2008 Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3 e3081 doi:10.1371/journal.pone.0003081

206. WilliamsonPRGambleCAltmanDGHuttonJL 2005 Outcome selection bias in meta-analysis. Stat Methods Med Res 14 515 524

207. KyzasPADenaxa-KyzaDIoannidisJP 2007 Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43 2559 2579

208. MartinBPaesmansMBerghmansTBranleFGhisdalLMascauxCMeertAPSteelsEVallotFVerdeboutJMLafitteJJSculierJP 2003 Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89 55 64

209. McShaneLMAltmanDGSauerbreiW 2005 Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97 1023 1025

210. AndreFMcShaneLMMichielsSRansohoffDFAltmanDGReis-FilhoJSHayesDFPusztaiL 2011 Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8 171 176

211. PetersJMengersenK 2008 Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof 31 370 389

212. SauerbreiWHolländerNRileyRDAltmanDG 2006 Evidence-based assessment and application of prognostic markers: The long way from single studies to meta-analysis. Commun Stat Theory Methods 35 1333 1342

213. RifaiNAltmanDGBossuytPM 2008 Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 54 1101 1103

214. NtzaniEEIoannidisJP 2003 Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362 1439 1444